Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$4.71 USD
-0.11 (-2.28%)
Updated May 8, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APLT 4.71 -0.11(-2.28%)
Will APLT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Other News for APLT
Applied Therapeutics GAAP EPS of -$0.67 misses by $0.51
Applied Therapeutics Reports First Quarter 2024 Financial Results
Applied Therapeutics reports Q1 EPS (67c), consensus (16c)
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond